

BCIL transferred ICMR technology for Shigella Vaccine to Hilleman Labs

BCIL facilitated licensing of Shigella Vaccine technology, developed by National Institute of Cholera and Enteric Diseases (NICED), Kolkata through ICMR support to MSD-Wellcome Trust Hilleman Laboratories Pvt. Ltd., New Delhi.

The licensing ceremony of Shigella Vaccine technology was held on 23rd of April 2019 at ICMR headquarters, New Delhi in presence of Dr. Balram Bhargava, DG, ICMR & Secretary DHR and Dr. Chandra Shekhar, Addl DG, ICMR.

Shigellosis is an infectious disease, marked by diarrhoea and fever caused by Shigella species with huge disease burden causing ~125 million diarrhoeal episodes annually, around 160,000 deaths, with a third of these associated with young children. Management of shigellosis includes improvement of sanitation, rehydration therapy and most essentially, antibiotic therapy. Considering the global emergence of multidrug resistance (MDR) and in absence of indigenously developed Shigella vaccine, developing this vaccine is the need of this hour and is a major break-through.

As per a recent market report, Shigella vaccine market is expected to reach USD 50.42 billion by 2023 from USD 34.45 billion in 2017 growing at a CAGR of 6.7%. The market size for this vaccine is approximately 2.3 billion globally and 19.8 million in India based on the number of children in the age of 0-6.

Till date there is no licensed vaccine for Shigellosis and treatment options are diminishing due to increasing resistance to key antimicrobials. In this scenario, vaccines are the only effective tool to fight against the disease. A group of researchers from NICED have developed a unique, broad spectrum vaccine against Shigellosis with effectiveness against 50 serotypes of Shigella to address the unmet market need of this vaccine. The shigella vaccine, developed by NICED-ICMR is expected to have a huge impact by largely benefiting children living in developing countries low-income and middle-income settings.



Licensing Ceremony of Shigella Vaccine Technology at ICMR Headquarters, New Delhi in the presence of Prof. Balram Bhargava, DG, ICMR and other dignitaries.

.....